AbbVie (NYSE:ABBV) Shares Down 3.8% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV) dropped 3.8% during trading on Wednesday . The company traded as low as $204.27 and last traded at $217.04. Approximately 15,265,070 shares traded hands during trading, an increase of 101% from the average daily volume of 7,604,316 shares. The stock had previously closed at $225.66.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised guidance — AbbVie reported adjusted Q4 EPS of $2.71 and revenue of $16.62B (both above consensus) and guided FY‑2026 adjusted EPS to $14.37–$14.57, underpinning near‑term earnings visibility. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Immunology momentum — Skyrizi and Rinvoq drove double‑digit growth in the immunology portfolio and helped lift overall revenue ~10% YoY; management says newer immunology sales helped beat expectations. AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
• Positive Sentiment: Pipeline expansion — AbbVie filed regulatory applications for Rinvoq (upadacitinib) in vitiligo, which would expand indications and provide additional growth optionality if approved. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®)
• Neutral Sentiment: Analyst positioning mixed but not uniformly negative — some firms (Evercore/others) maintain bullish views citing immunology momentum and neurology upside, supporting longer‑term conviction. AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
• Neutral Sentiment: Some commentators view the selloff as a buying opportunity given fundamentals and dividend/institional support, so technical buyers may step in at these levels. MarketBeat AbbVie coverage
• Negative Sentiment: Aesthetics and filler weakness — Allergan/Aesthetics (Botox/Juvederm) showed softer results and investor focus on “filler” weakness pressured the stock despite the companywide beat. AbbVie stock slides as investors focus on aesthetics weakness
• Negative Sentiment: Diversification concerns and a downgrade — some analysts question growth durability outside immunology as oncology and aesthetics declined, and one downgrade highlighted reliance on M&A and the exclusion of IPR&D/milestone costs from guidance. AbbVie’s Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade)
• Negative Sentiment: Profit‑taking despite beat — commentary notes that Rinvoq and some oncology lines missed investor expectations and management excluded acquired IPR&D/milestone impacts from guidance, keeping uncertainty around 2026 cash/earnings assumptions. This helped trigger the selloff. AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat ’26 View

Wall Street Analyst Weigh In

Several equities analysts have commented on ABBV shares. Evercore ISI reiterated an “outperform” rating and set a $228.00 price target on shares of AbbVie in a report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Morgan Stanley lifted their target price on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Finally, Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $251.50.

AbbVie Trading Down 3.8%

The company has a market cap of $383.59 billion, a price-to-earnings ratio of 164.42, a price-to-earnings-growth ratio of 0.93 and a beta of 0.35. The company has a fifty day moving average price of $224.20 and a two-hundred day moving average price of $219.16.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the company posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Institutional Trading of AbbVie

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Catalyst Financial Partners LLC lifted its position in shares of AbbVie by 5.8% during the 4th quarter. Catalyst Financial Partners LLC now owns 14,233 shares of the company’s stock worth $3,252,000 after buying an additional 785 shares during the period. Moneco Advisors LLC raised its stake in AbbVie by 5.2% during the fourth quarter. Moneco Advisors LLC now owns 18,164 shares of the company’s stock worth $4,150,000 after acquiring an additional 892 shares in the last quarter. Strategic Family Wealth Counselors L.L.C. lifted its holdings in shares of AbbVie by 65.0% during the fourth quarter. Strategic Family Wealth Counselors L.L.C. now owns 5,602 shares of the company’s stock valued at $1,199,000 after acquiring an additional 2,207 shares during the period. Biltmore Family Office LLC boosted its stake in shares of AbbVie by 2.5% in the 4th quarter. Biltmore Family Office LLC now owns 35,812 shares of the company’s stock valued at $8,183,000 after purchasing an additional 887 shares in the last quarter. Finally, Stonebridge Financial Group LLC MO bought a new stake in shares of AbbVie in the 4th quarter worth about $675,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.